A six-month double-blind, randomised, parallel-group study to compare the effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy (less than or equal to 15mg daily) on body fat distribution when administered to subjects with type 2 diabetes mellitus
Diabetes Mellitus, Type 2
Phase 4
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
March 2015